Innovacell Biotechnologie AG is an innovative company that concentrates on cell-tissue therapy for the treatment of incontinence. It currently has two personalised medical product sunder development in multi-national clinical studies, ICES13 and ICEF15. Innovacell has also successfully developed a minimally-invasive implantation method based on Sonoject®, a patented instrument which is guided by ultra-sound to re-inject a patient's own muscle cells. To date, more around 1,000 patients have been treated in clinical studies.
Pressemitteilung: 2015-02-09Capital injection for biotechnology company, Innovacell Major advances made in the clinical development of therapies to treat urinary and fecal incontinence. read more »